The FDA approved a new authorization for emergency use of coronary antibody therapy

U.S. Food and Drug Administration (FDA) approved a drug emergency use authorization on the 9th local time, antibody drug bamlanivimab (LY-CoV555) was approved for the treatment of new coronary pneumonia mild, medium-disease infection.
, according to USA Today, the FDA said the drug is intended for patients with mild and medium-aged coronary conditions 12 years of age and older, and not for new crown hospitalizations. This antibody therapy should be implemented as soon as possible after a positive new crown test or within 10 days of the onsaication of symptoms. According to the FDA, early studies have shown that obese people over the age of 65 are most effective in the treatment.
bamlanivimab is a drug developed by Lilly, a U.S. biopharmaceutical company. It is a monoclonal antibody that helps prevent viruses from attaching, entering cells and replicating.
clinical trial registration for the antibody therapy was suspended on October 14, according to
, and Lilly issued a statement saying there were potential safety issues with the therapy. However, a few days later, the National Institutes of Allergy and Infectious Diseases, part of the National Institutes of Health, said in a statement on October 26th that more careful studies had shown that the treatment was not a safety issue but was less effective for hospitalized patients.
The U.S. National Institute of Allergy and Infectious Diseases is the only scientific unit to evaluate the drug, which began trials in August to test the efficacy of its combination therapy with Redsyvir in patients with the new crown.
, according to US news website Politico, one of the main drawbacks of antibody therapy is that they are difficult to mass produce quickly. Experts such as Shreve, chief executive of Regeneration, and Gottlieb, the former head of the FDA, warn that antibody therapy drugs are not enough to meet demand.
, according to the media reports, Lilly developed bamlanivimab and regenerative meta company developed a new coronary monoant antibody mixture ("antibody cocktail") are artificial antibodies. U.S. President Donald Trump has under been subjected to an experimental "antibody cocktail" treatment during his infection with the new coronavirus. The Trump administration has signed hundreds of millions of dollars in agreements with the two companies to buy 300,000 doses of the drug each. The government says the drugs will be available free of charge to patients.